Journal article
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Abstract
BACKGROUND: Patients with diffuse large B-cell lymphoma that is refractory to primary and second-line therapies or that has relapsed after stem-cell transplantation have a poor prognosis. The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel targets and eliminates CD19-expressing B cells and showed efficacy against B-cell lymphomas in a single-center, phase 2a study.
METHODS: We conducted an international, phase 2, pivotal study …
Authors
Schuster SJ; Bishop MR; Tam CS; Waller EK; Borchmann P; McGuirk JP; Jäger U; Jaglowski S; Andreadis C; Westin JR
Journal
The New England Journal of Medicine, Vol. 380, No. 1, pp. 45–56
Publisher
Massachusetts Medical Society
Publication Date
January 3, 2019
DOI
10.1056/nejmoa1804980
ISSN
0028-4793